|
 |
TopamaxThis page contains recent news articles, when available, and an overview of Topamax but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Topamax (when available) Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. The precise mechanisms by which Topiramate exerts its anticonvulsant and migraine prophylaxis effects are unknown; however, preclinical studies have revealed four properties that may contribute to Topiramate's efficacy for epilepsy and migraine prophylaxis. Electrophysiological and biochemical evidence suggests that Topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABAA receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV. Used for the treatment of partial or primary generalized tonic-clonic seizures also used as a treatment for adults with partial-onset seizures. Also indicated for prophylaxis of migraine headaches Mechanism Of Action: Topiramate most likely exerts its actions by four mechanisms: (1) blockage of voltage-dependent sodium channels, (2) augmentation of the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABAA receptor, (3) antagonism of the AMPA/kainate subtype of the glutamate receptor, (4) inhibition of the carbonic anhydrase enzyme. News Articles on Topiramate Farmaci antiepilettici e gravidanza: il Valproato può essere ... - 30 Aug 2009 Un altro studio, pubblicato su Neurology, ha trovato che le donne che assumono Valproato assieme a Topiramato ( Topamax ) presentavano una probabilità 11 XagenaSalute J&J Would Rather Not Say - Aug 24, 2009 With US sales of its blockbuster epilepsy drug, Topamax, down 86% last quarter after Topamax started facing generic competition, Johnson & Johnson could Motley Fool Johnson & Johnson Epilepsy Drug Doesn't Win Clearance - Aug 21, 2009 Topamax, J&J's currently marketed anti-epileptic, had $2.7 billion in 2008 sales, according to data complied by Bloomberg. J&J is reviewing the letter from Bloomberg Fond du Lac woman convicted of stealing drugs from patient - Aug 20, 2009 During a subsequent search of Lindvall's vehicle, police found tablets of methadone, ritalin, oxycodone and topamax, according to the criminal complaint. The Reporter J&J consolidating management, eliminating biz unit - Aug 26, 2009 In addition, recent generic competition to schizophrenia drug Risperdal and Topamax for epilepsy has cut sales, forcing the company to reduce costs and The Associated Press Is Your Medicine Making You Fat? - Aug 28, 2009 Tunstall and her psychiatrist tried to rein in her constant eating—including adding a course of Topamax, an antiseizure medication known for its ability to Oprah.com Stonefly Communications Group Announces New Appointments - Aug 27, 2009 Weatherby has worked on healthcare brands such as Cymbalta, Alimta, Vidaza, Topamax and Razadyne. "We are thrilled that Stonefly has attracted such a PharmaLive.com (press release) Going, going, gone Patents set to expire soon on many brand-name drugs - Aug 7, 2009 A generic version of Topamax already has been approved by FDA. 3 GSK is evaluating in trials a spinoff Imitrex-plus-naproxen combination drug, Trexima, Modern Medicine About this author: - Aug 11, 2009 In addition the company has improved its ROE and other asset rations Several key pharma brands (in excess of 1 bn sales) such as risperdal and Topamax have Seeking Alpha Cempra Pharmaceuticals Announces Appointment of John H. Johnson to ... - Aug 12, 2009 ...development of sales, marketing and new product strategies of several of the company's flagship brands, including LEVAQUIN(R), ULTRAM(R) and TOPAMAX(R). PR Newswire (press release) While Some New Agents Will Achieve Strong Sales, the Migraine Drug ... - Aug 5, 2009 ...prescribed for the acute treatment of migraine attacks, and Ortho-McNeil/Janssen-Cilag's anti-epileptic drug Topamax, used for migraine prophylaxis, PR Newswire (press release) Migraine 'miracle worker' - Aug 11, 2009 Prior to seeing Phil he was taking Topamax: a pain relief used on patients who have had brain surgery. Every time he went back to the doctor, Sunshine Coast Daily Psychiatric Involvement in Obesity Treatment - Aug 28, 2009 Amantadine may lead to weight loss when used with olanzapine, and topiramate (Topamax) has been reported to counter weight gain caused by psychotropic Focus (subscription) J&J elimina a mais pequena das suas divisões - Aug 28, 2009 Por outro lado, a concorrência dos genéricos para o Risperidal® eo Topamax® forçou a companhia a reduzir custos ea equacionar cortes nos postos de trabalho, http://www.rcmpharma.com J&J í•ì „ê°„ì œ 카리스바메ì?´íŠ¸, 美 승ì?¸ 실패 - Aug 21, 2009 ...ì „ì„¸ê³„ í•ì „ê°„ì œ 시장ì?€ 169ì–µ 달러ì—? ì?´ë¥´ë©° ê·¸ 중 J&Jì?˜ 간질약ì?¸ 'í† íŒŒë§¥ìŠ¤(Topamax)'ì?˜ 2008ë…„ 매출ì?€ 27ì–µ 달러였다. J&J는 ë¯¸êµ FDAì?˜ 공문ì?„ ê²€í† í•˜ê³ ìžˆìœ¼ë©° 데일리팜 Johnson & Johnson's Profit Falls 3.5% - 14 Jul 2009 In an interview, Mr. Caruso said currency rates hurt the quarter's results the most, followed by lower sales of Risperdal and Topamax, each down two-thirds New York Times Stocks Advance, Bonds Decline Before Goldman Sachs Earnings - 14 Jul 2009 The maker of thousands of health-care products from Listerine mouthwash to Topamax migraine pills posted second-quarter profit of $1.15 a share, Bloomberg Johnson & Johnson Q2 2009 Earnings Call Transcript - 14 Jul 2009 The marketing exclusivity for TOPAMAX expired at the end of March this year and multiple generics have entered the market while generic competitors for Seeking Alpha Obama Hospital Deal Pressures Device Makers, J&J Says - 14 Jul 2009 ...companies to help reverse declining revenue after cheaper copies of the migraine treatment Topamax and the mood-stabilizer Risperdal entered the market. Bloomberg J&J Profit Tops Estimates on Sales of Listerine, Hips - 14 Jul 2009 The second quarter was the first full reporting period in which J&J faced generic competition to Topamax and Risperdal. The two drugs had combined revenue Bloomberg CIT Group Inc. (NYSE:CIT) Today's Top NYSE Stock To watch - 14 Jul 2009 2009, before the market opens, due in part to the recent loss of market exclusivity for its popular Topamax drug and slowed sales of consumer products. TransWorldNews (press release) Les profits de Johnson & Johnson supérieurs aux attentes - 14 Jul 2009 Les ventes ont plongé de 73% pour le Topamax, à 182 millions de dollars, et de 66% pour le Risperdal, à 239 millions. Des analystes remarquent cependant Le Point Johnson & Johnson reduce sus ganancias - 14 Jul 2009 Las ventas de Topamax se hundieron 73%, a 182 millones de dólares, mientras que las de Risperdal cayeron 66% a 239 millones de dólares. CNNExpansión.com è²¡å ±ï¼?嬌生Q2淨利微減至32億美元 表ç?¾å„ªæ–¼å¸‚å ´é ?期 - 14 Jul 2009 ...嬌生最近 有兩款å??åˆ—éŠ·å”®å† è»?çš„è—¥å“?，Risperdal å’ŒTopamax， å› å°ˆåˆ©å?³å°‡åˆ°æœŸè€Œå¤±åŽ»ä¿?è·ã€‚ RBC Capital 分æž?å¸«å‘¨ä¸€è¡¨ç¤ºï¼Œå› Topamax 近期喪 å¤±å¸‚å ´å°ˆåˆ©ï¼Œé ?期嬌生藥å“? 鉅亨網 Corr.: Johnson & Johnson noteert $58,18, niet EUR58,18 - 14 Jul 2009 Dat kwam vooral doordat vorig jaar twee exclusieve patenten afliepen van het medicijn Risperdal (tegen psychoses) en Topamax (tegen epilepsie en migraine). Financieele Dagblad 强生第二å£ç›ˆåˆ©ä¸‹é™? é‡?申全年预期 - 14 Jul 2009 ...该公å?¸çš„两款畅销产å“?——Risperdal与Topamax——最近失去了专利ä¿?护。 抗精神病è?¯ç‰©Risperdalçš„å…¨ç?ƒé”€å”®é¢?下é™?66%，至2.39亿美元；抗癫痫è?¯Topamax的销售é¢?下é™?了73%， 新浪网 Печалбата на Johnson&Johnson пада Ñ? 3.6% - 14 Jul 2009 Johnson&Johnson Ñ?е опитва да навакÑ?а изоÑ?таването в приходите, Ñ?лед като по-евтини копиÑ? на лекарÑ?твата й като Topamax и Risperdal навлÑ?зоха на пазара. Пари EUA: Lucro da Johnson & Johnson recua 3,6% mas supera previsões - 14 Jul 2009 A concorrência dos genéricos em medicamentos com o Topamax, comprimidos para as dores de cabeça, presionaram os resultados da empresa. Expresso Beter dan verwachte resultaten Johnson & Johnson - 14 Jul 2009 Vooral Topamax, een medicijn voor de bestrijding van migraine, en Risperdal, voor stemmingswisselingen af te vlakken, hebben met toenemende concurrentiële Cash.be Defenzivnà titul Johnson Johnson pÅ™ekonal oÄ?ekávánà trhu - 14 Jul 2009 NejvýraznÄ›jÅ¡Ã propad byl zaznamenán u léku Topamax (léÄ?ba epilepsie) a Risperdal (použÃvaný pÅ™i léÄ?bÄ› psychóz). DalÅ¡Ãm negativnÃm vlivem je snižujÃcà se Finance.cz Wyniki Johnson & Johnson nieco powyżej oczekiwaÅ„ - 14 Jul 2009 Powodem takiego spadku jest wzrost sprzedaży taÅ„szych odpowiedników leków produkowanych przez spółkÄ™ - leku migrenowego Topamax oraz leku stabilizujÄ…cego Parkiet J&J leidet im 2Q unter Wechselkursen und Generika - 14 Jul 2009 Der US-Pharmakonzern leidet darunter, im März den Patentschutz für das Epilepsiemittel Topamax und im vergangenen Jahr den Schutz für das FOCUS Online Johnson & Johnson Expected To Report Lower 2Q Earnings - Jul 13, 2009 ...earnings Tuesday, due in part to the recent loss of market exclusivity for its popular Topamax drug and slowed sales of consumer products. Wall Street Journal Earnings Preview: J&J sales seen down for 3rd time - Jul 10, 2009 This quarter, generic competition will sharply cut revenue of two top drugs, antipsychotic drug Risperdal and epilepsy treatment Topamax, which also The Associated Press Pain Management in Acute Care - Jul 13, 2009 Newer anticonvulsants such as gabapentin (Neorontin ® , Parke Davis), topiramate (Topamax ® , Ortho-McNeil Pharmaceutical), lamotrigine (Lamictal ® ADVANCE for LPNs Quiz: Are you a savvy health care consumer? - Jul 2, 2009 ...(a) Prevacid, Topamax, and Valtrex will lose patent protection this year, paving the way for sales of generic copies, which can cost 30 to 80 percent less. LaSalle News Tribune EU Panel Recommends ChondroCelect Get Marketing Authorisation - Jun 26, 2009 ...-Topamax and associated names, (topiramate), from Johnson & Johnson group of companies and associated companies, used as an anti-convulsant. CNNMoney.com Switching Off Headaches - Jul 6, 2009 Chronic daily headaches may also be treated with anti-seizure medications such as divalproex (Depakote), gabapentin (Neurontin) or topiramate (Topamax). WFtv.com No More Tears for J&J - Jun 18, 2009 Prescription drug sales are losing ground as top-selling drugs Risperdal and Topamax fall victim to generic rivals and safety issues sap sales of the anemia Barron's From staff reports - Jun 20, 2009 ...(SJCSO) * What: Topamax, Lexapro and Ambien pills, gold wedding band. Value: $363. Where, when: 100 block E. Vistana Drive, June 14. St. Augustine Record TAKING STEPS TOWARD EPILEPSY - Jun 30, 2009 The studies showed that Vimpat provided control of partial seizures when added to the broadest range of AEDs-including Keppra® (levetiracetam), Topamax® North American Press Syndicate Vivus(VVUS) is in the driver's seat for obesity experiental drug 2 ... - Jul 7, 2009 Qnexa is a combination of two existing drugs, phentermine and topiramate (marketed for epilepsy and migraine as Topamax). Contrave is a combination of Seeking Alpha Sexo al gusto y sin embarazo - Jun 30, 2009 ...los anticonvulsivos como topiramate (Topamax), carbamazepina (Tegretol), fenitoina (Dilantin) o fenilbutazona (Butazolidin) y ciertos medicamentos Metro Noticias de Tamaulipas Epilessia: gli antiepilettici associati a ideazione suicidaria e ... - Jul 8, 2009 Pregabalin ( Lyrica ), Tiagabina ( Gabitril ), Topiramato ( Topamax ), Valproato ( Depakote, Depakin ), Zonisamide ( Zonegran ). ( Xagena Medicina ) XagenaSalute Brand Names/Synonyms: Topamax is also known by the following brand names and/or synonymsCHEMBANK1823; Mcn-4853; Tipiramate [French]; Tipiramato [Spanish]; Topamax; Topamax Sprinkle; Topiramate; Topiramate [Usan:Ban:Inn]; Topiramato [Inn-Spanish]; Topiramatum [Inn-Latin]; Topiramatum [Latin] Drug Category: Topamax is categorized under the following by the FDA: Antiobesity Agents; Neuroprotective Agents; Anticonvulsants; ATC:N03AX11 Dosage Forms: CAPSULE; TABLET Absorption: Rapid with pleak plasma concentrations occurring after 2 hours. Bioavailability is 80% Interactions: Interactions for Topiramate: In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes. Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 3. In Table 3, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when Topiramate was given alone. Table 3: Summary of AED Interactions with Topiramate AED Co-administered AED Concentration Topiramate Concentration Phenytoin NC or 25% increasea 48% decrease Carbamazepine (CBZ) NC 40% decrease CBZ epoxide NC NE Valproic acid 11% decrease 14% decrease Phenobarbital NC NE Primidone NC NE Lamotrigine NC at TPM doses up to 400 mg/day 15% increase NC = Less than 10% change in plasma concentration. AED = Antiepileptic drug. NE = Not Evaluated. TPM = Topiramate In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy. Other Drug Interactions Digoxin: In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant Topiramate administration. The clinical relevance of this observation has not been established. CNS Depressants: Concomitant administration of Topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse events, topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants. Oral Contraceptives: In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), Topiramate given in the absence of other medications at doses of 50 to 200 mg/day was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, Topiramate (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose dependent decrease in EE exposure for doses between 200-800 mg/day, there was no significant dose dependent change in EE exposure for doses of 50-200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with Topiramate. Patients taking estrogen containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding. Metformin: A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin and topiramate in plasma when metformin was given alone and when metformin and topiramate were given simultaneously. The results of this study indicated that metformin mean Cmax and mean AUC0-12h increased by 18% and 25%, respectively, while mean CL/F decreased 20% when metformin was co-administered with topiramate. Topiramate did not affect metformin tmax. The clinical significance of the effect of topiramate on metformin pharmacokinetics is unclear. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The extent of change in the clearance is unknown. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear. When Topiramate is added or withdrawn in patients on metformin therapy, careful attention should be given to the routine monitoring for adequate control of their diabetic disease state. Lithium: Multiple dosing of topiramate 100 mg every 12 hrs decreased the AUC and Cmax of Lithium (300 mg every 8 hrs) by 20% (N=12, 6 M; 6 F). Haloperidol: The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 M, 7 F). Amitriptyline: There was a 12% increase in AUC and Cmax for amitriptyline (25 mg per day) in 18 normal subjects (9 male; 9 female) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels. Sumatriptan: Multiple dosing of topiramate (100 mg every 12 hr) in 24 healthy volunteers (14 M, 10 F) did not affect the pharmacokinetics of single dose sumatriptan either orally (100 mg) or subcutaneously (6 mg). Risperidone: There was a 25% decrease in exposure to risperidone (2 mg single dose) in 12 healthy volunteers (6 M, 6 F) receiving 200 mg/day of topiramate. Therefore, patients receiving risperidone in combination with topiramate should be closely monitored for clinical response. Propranolol: Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 M, 17 F) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27M, 12F) had no affect on the exposure to topiramate at a dose of 200 mg/day of topiramate. Dihydroergotamine: Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 M, 12 F) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study. Others: Concomitant use of Topiramate, a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e. g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided. Drug/Laboratory Tests Interactions: There are no known interactions of topiramate with commonly used laboratory tests. Chemical IUPAC Name: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |